We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Iridium Electrode Generates Therapeutic Nitric Oxide from Thin Air

By HospiMedica International staff writers
Posted on 12 Aug 2015
A lightweight, portable device could provide effective treatment of pulmonary hypertension by generating nitric oxide (NO), according to a new study. More...


Researchers at Massachusetts General Hospital (MGH; Boston, MA, USA) developed two generators—an offline and an inline version—that can serve as a simple and economical method of producing pure NO from air. The offline generator can be used to store NO, while the inline generator can be placed directly on the inspiratory line of a mechanical ventilator or anesthesia machine for bedside or portable use. Both use pulsed electrical discharges to produce therapeutic range NO (5 to 80 ppm) at gas flow rates of 0.5–5 L/min, but also other gas mixtures containing up to 90% O2 and 10% N2.

Potentially toxic gases such as nitrogen dioxide (NO2) and ozone (O3), as well as metal fragments from the electrode are removed using a calcium hydroxide scavenger. Further testing revealed that an iridium spark electrode produced the lowest ratio of NO2/NO. In in-vivo tests on lambs with acute pulmonary hypertension showed that breathing the electrically generated NO caused pulmonary vasodilation and reduced pulmonary arterial pressure and vascular resistance index. Both offline and inline systems delivered therapeutic levels of NO for up to 10 days. The study was published in the July 1, 2015, issue of Science Translational Medicine.

“NO therapy is very expensive, and current systems use gas delivered in heavy tanks, making ambulatory treatment impractical. Our new system can economically make NO from the nitrogen and oxygen in the air using only small amounts of electric power,” said lead author Warren Zapol, MD, director of the MGH Anesthesia Center for Critical Care Research. “This device could enable trials of NO to treat patients with chronic lung diseases and certain kinds of heart failure and would make NO therapy available in parts of the world that don’t have the resources that are currently required.”

NO is a ubiquitous signaling molecule that is crucial for the control of blood pressure, blood flow, and other vital bodily functions. NO is also a powerful vasodilator with a short half-life of a few seconds, which works by signaling the smooth muscle surrounding blood vessel endothelium to relax, thus resulting in vasodilation and increasing blood flow. Inhalation of NO has been found to be an effective therapy for treating pulmonary hypertension in adults and pulmonary hypertension of the newborn (PPHN).

Related Links:

Massachusetts General Hospital



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.